4D Molecular Therapeutics FDMT Deferred Tax Assets and Other Non-Current Assets
Deferred Tax Assets and Other Non-Current Assets at other companies
Other financials
Where this comes from
Reported directly by 4D Molecular Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:OtherAssetsNoncurrent.
The official record: 4D Molecular Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about 4D Molecular Therapeutics's deferred tax assets and other non-current assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is 4D Molecular Therapeutics's deferred tax assets and other non-current assets?
- 4D Molecular Therapeutics (FDMT) reported deferred tax assets and other non-current assets of $9.86M in Q1 2026.
- How has 4D Molecular Therapeutics's deferred tax assets and other non-current assets changed year-over-year?
- 4D Molecular Therapeutics's deferred tax assets and other non-current assets increased by 40.0% year-over-year, from $7.04M to $9.86M.
- What is the long-term trend for 4D Molecular Therapeutics's deferred tax assets and other non-current assets?
- Over 5 years (2020 to 2025), 4D Molecular Therapeutics's deferred tax assets and other non-current assets has grown at a 72.5% compound annual growth rate (CAGR), from $602K to $9.19M.